Literature DB >> 7913384

Why not octreotide?

S Mercadante.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7913384     DOI： 10.1007/bf00417484

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  6 in total

1.  Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients.

Authors:  S Mercadante; S Maddaloni
Journal:  J Pain Symptom Manage       Date:  1992-11       Impact factor: 3.612

2.  Control of emesis in bowel obstruction in terminally ill patients.

Authors:  D Khoo; J Riley; J Waxman
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

3.  Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer.

Authors:  F Stiefel; R Morant
Journal:  Support Care Cancer       Date:  1993-01       Impact factor: 3.603

4.  Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.

Authors:  S Mercadante; E Spoldi; A Caraceni; S Maddaloni; M T Simonetti
Journal:  Palliat Med       Date:  1993       Impact factor: 4.762

5.  Management of bowel obstruction in advanced and terminal cancer patients.

Authors:  C Ripamonti; F De Conno; V Ventafridda; B Rossi; M J Baines
Journal:  Ann Oncol       Date:  1993-01       Impact factor: 32.976

Review 6.  The role of octreotide in palliative care.

Authors:  S Mercadante
Journal:  J Pain Symptom Manage       Date:  1994-08       Impact factor: 3.612
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.